DURECT CORPORATION (DRRX) Stock News

USA - NASDAQ:DRRX - US2666055007 - Common Stock

1.91 USD

-0.02 (-1.04%)

Last: 9/10/2025, 8:00:01 PM

1.94 USD

+0.03 (+1.57%)

After Hours: 9/10/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DRRX Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Yahoo Finance - Mentions: BHC

Bausch Health Companies Inc. (BHC) Expands Hepatology Portfolio with DURECT Acquisition

2 months ago - By: ACCESS Newswire - Mentions: BHC BHC.CA

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

2 months ago - By: The Motley Fool

Durect Posts Narrower Loss in Fiscal Q2

a year ago - By: Benzinga

An Overview of Durect's Earnings

a year ago - By: Benzinga

Earnings Preview: Durect

a year ago - By: BusinessInsider

News Image

DRRX Stock Earnings: Durect Beats EPS, Misses Revenue for Q2 2024

a year ago - By: InvestorPlace

DRRX Stock Earnings: Durect Beats EPS, Misses Revenue for Q2 2024

3 months ago - By: Zacks Investment Research - Mentions: CATX

Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: DURECT Corporation

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

3 months ago - By: Yahoo Finance - Mentions: BHC

Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment

3 months ago - By: Halper Sadeh LLC

DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders

3 months ago - By: Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders

3 months ago - By: DURECT Corporation - Mentions: BHC

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

6 months ago - By: DURECT Corporation

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Zacks Investment Research - Mentions: CPRX

Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates

7 months ago - By: DURECT Corporation

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

7 months ago - By: DURECT Corporation

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

9 months ago - By: DURECT Corporation

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

9 months ago - By: DURECT Corporation

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

a year ago - By: DURECT Corporation

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

a year ago - By: DURECT Corporation

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

a year ago - By: DURECT Corporation

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

a year ago - By: DURECT Corporation

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

a year ago - By: DURECT Corporation

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

a year ago - By: DURECT Corporation

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

a year ago - By: DURECT Corporation

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update